Of these 27 products, 17 are allogeneic, meaning the cells from a single healthy donor are used to treat multiple patients, while only 10 are autologous, i.e., the donor is the patient, displaying a clear trend towards allogenic.
← all excerpts
Mesenchymal and induced pluripotent stem cell-based therapeutics: a comparison.
1
—
—